CLINICAL EFFECTIVENESS AND COST-ANALYSIS OF NEW ORAL ANTIDIABETICS IN A COHORT OF TYPE 2 DIABETIC PATIENTS FROM A CARDIOVASCULAR RISK PROGRAM IN COLOMBIA

被引：0
|
作者：
Echeverri, E. [1 ]
Ruiz, A. J. [2 ]
Rondon, M. [2 ]
Echeverri, S. [3 ]
Rosselli, D. [2 ]
机构：
[1] Pontificia Univ Javeriana, Cali, Colombia
[2] Pontificia Univ Javeriana, Bogota, Colombia
[3] Sci Po, Paris, France
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO191
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [1] Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics
    Risebrough, Nancy A.
    Baker, Timothy M.
    Zhang, Lirong
    Ali, Sarah N.
    Radin, Michael
    Dang-Tan, Tam
    CLINICAL THERAPEUTICS, 2021, 43 (11) : 1812 - +
  • [2] COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO INSULIN DETEMIR FROM ORAL ANTIDIABETICS OR NPH IN THE CZECH SETTING; DATA FROM THE PREDICTIVE STUDY
    Dolezal, T.
    Pisarikova, Z.
    Rychna, K.
    Honka, M.
    Bartaskova, D.
    VALUE IN HEALTH, 2009, 12 (03) : A100 - A100
  • [3] Cost Effectiveness Analysis of a Hypertension Management Program in Patients With Type 2 Diabetes
    Ly, David
    Alex, Fu Z.
    Christopher, Hebert
    JOURNAL OF CLINICAL HYPERTENSION, 2009, 11 (03): : 116 - 124
  • [4] THERAPEUTIC INERTIA IN THE TREAMENT OF PATIENTS WITH TYPE 2 DIABETES IN A CARDIOVASCULAR RISK MANAGEMENT COHORT FROM THE CARIBBEAN REGION OF COLOMBIA
    Mejia, Salcedo F.
    Carrasquilla, M.
    Padilla, Parra D.
    Alvis-Zakzuk, N. J.
    Alvis-Guzman, N.
    De La Hoz, F.
    VALUE IN HEALTH, 2020, 23 : S120 - S120
  • [5] A modelled cost-effectiveness analysis of switching patients with poorly controlled type 2 diabetes to insulin detemir from oral antidiabetics or NPH in the Austrian setting; Data from the predictive study
    Stechemesser, L.
    Weitgasser, R.
    Hofmann, M.
    Aagren, M.
    Mihaljevic, R.
    VALUE IN HEALTH, 2008, 11 (03) : A227 - A227
  • [6] Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia
    Cristian Alejandro González-Rojas
    Sergio Augusto Cáceres-Maldonado
    Luis Alberto Soler-Vanoy
    Lizbeth Alexandra Acuña-Merchán
    Cost Effectiveness and Resource Allocation, 23 (1)
  • [7] DAPAGLIFLOZIN VERSUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA: COST-EFFECTIVENESS ANALYSIS
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [8] Improved effectiveness in the management of cardiovascular risk among type 2 diabetic patients in primary health care
    Hormigo Pozo, Antonio
    Viciana Lopeza, Maria Angeles
    Gomez Jimenez, Leonor
    Gallego Parrilla, Maria Dolores
    Orellana Lozano, Javier
    Morales Asencio, Jose Miguel
    ATENCION PRIMARIA, 2009, 41 (05): : 240 - 245
  • [9] THE LONGTERM COST EFFECTIVENESS OF THE "COACHING PATIENTS ON ACHIEVING CARDIOVASCULAR HEALTH" (COACH) PROGRAM IN TYPE 2 DIABETES IN TASMANIA
    Palmer, A. J.
    Vale, M. J.
    Wells, C. L.
    Ski, C.
    Thompson, D. R.
    Si, L.
    VALUE IN HEALTH, 2016, 19 (07) : A899 - A899
  • [10] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
    Pawlik, D.
    Wojcik, R.
    Zawodnik, A.
    Kaczor, M. P.
    VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
12345